Clinical Trial Detail

NCT ID NCT04434196
Title A Safety and Preliminary Efficacy Study of CC-99282 in Combination With Obinutuzumab in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Celgene
Indications

CLL/SLL

Therapies

CC-99282 + Obinutuzumab

Age Groups: adult senior

No variant requirements are available.